On the other hand, the work of Sugarman and collaborators reported that cannabinoids can cause inhibition of the release of acetylcholine, contributing to acute cognitive deficits by binding to the presynaptic CB1-R located in cholinergic nerve terminals (Sugarman et al., 2019). The gene discussed is CNR1; the disease is Cognitive impairment.